NeuBase Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

12 Months Ended

Sep. 30, 2019

Summary of stock options issued and outstanding

Below is a table summarizing the options issued and outstanding as of and for the year ended September 30, 2019:


			Weighted	Weighted Average
			Average	Remaining
			Exercise	Contractual Term (in		Total Aggregate
	Stock Options		Price	years)		Intrinsic Value
Outstanding as of September 30, 2018	—	$	—	0		—
Assumed in connection with license acquired- Ohr	106,000		13.31
Granted	6,269,966		2.52
Outstanding at September 30, 2019	6,375,966	$	2.70	9.4	$	16,650,319
Exercisable as of September 30, 2019	4,117,187	$	1.23	9.2	$	16,650,319

Schedule of key assumptions used to estimate the fair value of the stock options granted

Key assumptions used to estimate the fair value of the stock options granted during the year ended September 30, 2019 included:


		Year ended
		September 30,
		2019
Expected common stock price volatility		75.6% - 78.4%
Risk-free interest rate		1.8% - 2.5%
Expected term of options (years)		1.6 - 7
Expected dividend yield		—

Summary of changes in the outstanding restricted stock

A summary of the changes in the outstanding restricted stock during the year ended September 30, 2019 is as follows:


			Weighted
			Grant Date
		Unvested Restricted	Fair Value
		Stock	Price
Outstanding as of September 30, 2018		—	$	—
Granted		1,532,984		1.31
Vested		(1,526,109)		1.29
Non vested at September 30, 2019		6,875	$	6.24
Total unrecognized expense remaining	$	39,138
Weighted-average years expected to be recognized over		0.5

Schedule of stock-based compensation expense

The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the year ended September 30, 2019 and for the period from August 28, 2018 (inception) to September 30, 2018:


			For the Period From
			August 28, 2018
	For the Year Ended		(Inception) to
	September 30,		September 30,
	2019		2018
General and administrative expenses	$	6,543,575	$	—
Research and development expenses		3,241,508		—
	$	9,785,083	$	—